Public Companies
Irwin Naturals Mental Health Clinics to Enter Pacific Northwest
The company agreed to acquire a clinic in Washington.
The post Irwin Naturals Mental Health Clinics to Enter Pacific Northwest appeared first on Green…
Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) will expand its chain of psychedelics mental health clinics into the Pacific Northwest. The company reached a binding, arm’s length agreement to acquire the assets of Tri-Cities Infusion & Wellness Clinic PLLC, which is located in Kennewick, Washington.
The acquisition is an all-stock deal, but the total consideration will not be released until close.
This will be the first facility in Washington for Irwin Naturals Emergence and the 17th facility the chain has signed on or acquired across eight different states.
“We believe this type of treatment has the capacity to change the way we care for mental health in this country,” Klee Irwin, CEO of Irwin Naturals, said in a news release. “We’ve sought to move to the front of this market by moving fast while also being incredibly selective.”
Tyler Thornock and Ben Clark are the co-owners of the clinic, which opened in April 2019. Both are certified registered nurses with special training for anesthesia.
The clinic offers ketamine infusion, which has been used to treat a variety of mood disorders. It also offers nutrient IV infusions, aesthetic procedures, and regenerative treatments such as platelet-rich plasma injections.
The chain, Irwin Naturals Emergence, previously announced agreements with a total of 16 clinics located in seven different states. Last month, it announced an acquisition agreement with a clinic in Idaho.
The post Irwin Naturals Mental Health Clinics to Enter Pacific Northwest appeared first on Green Market Report.
ketamine psychedelics cse otc deal irwin naturals-
LSD1 week ago
The First Wave of Blotter Acid Inspired Trippy Psychedelic Art
-
Psilocybin1 week ago
Psychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics6 days ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics6 days ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Psychedelics5 days ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Ketamine5 days ago
DEA poised to move cannabis to Schedule III
-
Law & Regulation4 days ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics5 days ago
Behold! A New Mushroom Emoji Has Arrived!